ATYR SEC Filings: 8-K, 10-Q, S-3 & 424B – aTyr Pharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

aTyr Pharma Files Prospectus Supplement for Up to $79.9 Million Common Stock Offering

Nov 6, 2026

8-K

aTyr Pharma Reports Third Quarter 2026 Results and Corporate Updates

Nov 5, 2026

8-K

aTyr Pharma Announces 1-for-40 Reverse Stock Split

Oct 27, 2026

8-K

aTyr Pharma, Inc. Reports Voting Results from 2026 Special Meeting of Stockholders

Oct 16, 2026

8-K

aTyr Pharma Reaches Alignment with FDA on Phase 3 Study Protocol for Efzofitimod in Pulmonary Sarcoidosis

Sep 24, 2026

8-K

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring

Aug 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* November 2026 ATM | Offering amount: $79,994,251 | Bank: Jefferies LLC

Nov 6, 2026

424B5

ATM | Offering amount: $150,000,000 | Amount sold to date: $47,800,000

Dec 23, 2024

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Nov 9, 2023

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 9, 2023

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Feb 8, 2023

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Apr 22, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 7, 2025

S-3

August 2025 SHELF EFFECTIVE, DATED 2025-08-18

Aug 7, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 13, 2024

S-3

Form S-3 - Registration statement under Securities Act of 1933

Nov 9, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 10, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Sep 11, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Aug 31, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 26, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 26, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 12, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 19, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FEDERATED HERMES, INC. (Filed by)

Nov 4, 2026

SCHEDULE 13G/A

FEDERATED HERMES, INC. (Filed by)

Oct 7, 2026

Yaras Brandon (Reporting)

Oct 1, 2026

Yaras Brandon (Reporting)

Oct 1, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Aug 6, 2026

SCHEDULE 13G/A

BlackRock, Inc. (Filed by)

Jul 27, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 19, 2025

CORRESP

Form CORRESP - Correspondence

Aug 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jun 25, 2024

CORRESP

Form CORRESP - Correspondence

Jun 18, 2024

LETTER

Form UPLOAD - SEC-generated letter

Jun 6, 2024

aTyr Pharma, Inc. ATYR · SEC Filings